Catalog Products » Antibodies » Primary Antibodies » Phospho-Specific Antibodies » BRAF Antibody, mAb, Mouse

BRAF Antibody, mAb, Mouse

*This product has been discontinued! *
Synonyms Mouse Anti-BRAF mAb;
Description BRAF (V-raf murine sarcoma viral oncogene homolog B1) is the main effector recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites, Ser364, Ser428, and Thr439. B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK). It has a long amino-terminal region, which is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf can propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highest levels in the cerebrum and testes. Defects in BRAF are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma, melanocytic nevi, primary cutaneous melanomas, and colorectal cancers.
Host Species Mouse
Antigen Species Human
Immunogen Ni-NTA purified truncated recombinant BRAF expressed in E. coli strain BL21 (DE3).

Subclass IgG1
Clone ID A00774.01
Concentration Ascitic fluid containing 0.03% sodium azide
Specificity Truncated recombinant BRAF/K562 cell lysate (WB), BRAF recombinant protein (ELISA), Human bladder/lung carcinoma tissue (IHC)
Storage This product remains stable for one to two weeks if stored at 2°C to 8°C. Aliquot and store at -20°C or below for longer periods. Avoid repeated freezing and thawing cycles. Use within one year of the delivery date.

Western blot: 1: 500-1:1,000
IHC(P): 1:500-1:1,000
ELISA: Proposed dilution 1:10,000
Determine optimal working dilutions by titration test.
Technical Manual ELISA Protocol(pdf)
Western Blot Protocol(pdf)
FACS Protocol(pdf)
IHC Protocol(pdf)
IP Protocol(pdf)

Vida Khatamianfar.,et al. Trim59, A Novel Multiple Cancer Biomarker For Immunohistochemical Detection Of Tumorigenesis.BMJ Open.2012Otc;2(5):e001410

MS Khan, et al. Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer. Mutagenesis. 2014Jan.;

You can visit "Citations Database" for more citations.

For more documents, please visit "Technical Support".